AMID Co, April 2009, Pages: 199
Banking System and Regulations
Foreign Exchange
Taxes, Tariff and Custom Duties
III.ALZHEIMER’S DISEASE DRUGS INDUSTRY ASSESSMENTSAlzheimersDisease Drugs Industry Structure
Market Size
Datamonitor, Jan 2012, Pages: 32
is highest.
Scope:
- Gain insight into market potential, including a robust 10-year epidemiology forecast of Alzheimer’s disease prevalent cases.
- Understand the key epidemiologic risk factors associated
Greystone Associates, Aug 2011
challenging areas of therapeutic medicine. Patients diagnosed with conditions such as schizophrenia, Alzheimer's disease, Parkinson's disease, and manic depressive disorder are often not physically
Business Insights, Jan 2011, Pages: 130
cancer
Metastatic breast cancer
Response to therapy
Prognosis
Alzheimer’s disease
Prediction of AD
Detection of AD
Imaged-based biomarkers in AD
Market forecasts
Biomarkers and risks
Driving
Jain PharmaBiotech, May 2012, Pages: 633
.
Pathomechanisms of diseases are described with steps at which neuroprotective therapies are directed. Diseases covered include cerebrovascular disorders, traumatic brain injury, spinal cord injury, Alzheimer
Greystone Associates, March 2009, Pages: 180
chain (ecosystem) companies
- Provides detailed assessments of more than thirty patch products in more than a dozen product categories
- Charts product sales data, market share, and forecasts to 2012
STIX Market Research, May 2007, Pages: 116
deficiency syndrome—AIDS, HIV infection and tuberculosis), psychiatric disorders (depression and Alzheimer’s disease) and respiratory diseases (asthma and chronic obstructive pulmonary disease—COPD
Seed Planning, July 2007, Pages: 403
nationwide Japanese patient population statistics for all categories of diseases.
This book is designed to benefit people who are involved in searching patient population aiming to assess relevant markets
Life Science Intelligence, Inc., Jan 2011
- 48 Vascular Companies
- 26 Wound Management Companies Brief technology descriptions for companies covered:
- Image analysis for the diagnosis of Alzheimer's and other diseases
- Advanced over
Jain PharmaBiotech, May 2012, Pages: 1037
disorders by examination of proteins in the blood
Diagnosis of CNS disorders by examination of proteins in tears
Role of proteomics in the diagnosis of Alzheimer's disease
Role of proteomics
Business Insights, July 2010, Pages: 118
The Future Of Enteral Nutrition: Key Players, Disease Specific Opportunities and Market Forecasts Fuelled by an aging population and rising rates of illness, the clinical nutrition markets in the US
Frost & Sullivan, Sep 2009, Pages: 107
growth among the disease areas. Central nervous system (CNS) biomarkers are also not far behind, and have been found to have excellent growth potential mainly due to the tremendous thrust in Alzheimer
Espicom Business Intelligence Ltd, June 2009, Pages: 110
was responsible for research projects ranging from Alzheimer’s disease to schizophrenia. Dr Barton subsequently joined Dutch investment bank ABN Amro NV as a senior equity analyst where she was lead analyst
Business Insights, Aug 2007, Pages: 154
-medication and treatment.
- Increasing consumer belief in ‘you are what you eat’ driven by the availability of information about health, such as the rising levels of obesity, stress and Alzheimer’s disease
Markets and Markets, Sep 2009, Pages: 256
in the reimbursement systems
6.10.2. The costs for diagnostics are starting to be offset against the savings in other areas
6.10.2.1. Alzheimer’s disease
6.10.2.1.1. Image based biomarkers
6.10.2.1.2. Genetic Markers
